Refine
Document Type
- Article (6)
Has Fulltext
- yes (6)
Is part of the Bibliography
- no (6)
Keywords
- Active middle ear implants (1)
- Aedes aegypti (1)
- Anopheles stephensi (1)
- Auditory system (1)
- Bone conduction devices (1)
- Consensus statement (1)
- Crohn’s disease (1)
- GWAS (1)
- Gene expression (1)
- Health policy (1)
- Lockstoffe (1)
- Mesenchymal stem cells (1)
- Mixed hearing loss (1)
- Multi-stakeholder approach (1)
- Mückenmonitoring (1)
- NOD2 (1)
- Rehabilitation (1)
- Stegomyia aegypti (1)
- Surgery (1)
- Technical data (1)
- Trichuris suis ova (1)
- antiepileptic drugs (1)
- attractants (1)
- genetic generalized epilepsy (1)
- helminths (1)
- innate immunity (1)
- lamotrigine (1)
- levetiracetam (1)
- mosquito monitoring (1)
- pharmacoresistance (1)
- valproic acid (1)
Institute
- Medizin (4)
Nowadays, several options are available to treat patients with conductive or mixed hearing loss. Whenever surgical intervention is not possible or contra-indicated, and amplification by a conventional hearing device (e.g., behind-the-ear device) is not feasible, then implantable hearing devices are an indispensable next option. Implantable bone-conduction devices and middle-ear implants have advantages but also limitations concerning complexity/invasiveness of the surgery, medical complications, and effectiveness. To counsel the patient, the clinician should have a good overview of the options with regard to safety and reliability as well as unequivocal technical performance data. The present consensus document is the outcome of an extensive iterative process including ENT specialists, audiologists, health-policy scientists, and representatives/technicians of the main companies in this field. This document should provide a first framework for procedures and technical characterization to enhance effective communication between these stakeholders, improving health care.
Stechmücken der Art Stegomyia aegypti (ehemals Aedes aegypti, REINERT et al. 2004) sind die wichtigsten Überträger von Gelbfieber- und Dengueviren. Diverse Arten der Gattung Anopheles verbreiten die Erreger der Malaria. Bei Versuchen, Malaria, Gelbfieber und Dengue einzudämmen, wurden in den letzten Jahrzehnten wiederholt Kampagnen gegen Stechmücken geführt. Dabei wurden Insektizide vielfach flächendeckend ausgebracht. Dies führte kurzfristig zu geringeren Mückendichten, allerdings entwickelten sich auch vielerorts gegen diese Gifte resistente Mückenpopulationen. Anstelle des flächendeckenden Gifteinsatzes wird heute versucht, die Insektizide örtlich und zeitlich effektiv einzusetzen, um so die Gefahr weiterer Resistenzbildung zu minimieren und sowohl die Kosten als auch die Belastung für Umwelt und Bevölkerung möglichst gering zu halten. Um Insektizide zur richtigen Zeit gezielt ausbringen zu können, ist ein Monitoring der Mücken erforderlich. Mückenfallen, die durch optische Effekte und Duftstoffe gezielt anthropophile Stechmückenarten anlocken, sind für ein derartiges Bestandsmonitoring besonders geeignet. Auf der Suche nach attraktiven Duftstoffen, welche die Effektivität solcher Fallen erhöhen, wurde unter anderem auch 2-Undecanon getestet. In Verhaltensversuchen mit den anthropophilen Mückenarten Stegomyia aegypti und Anopheles stephensi konnte die Attraktivität dieser Substanz sowohl als Einzelreiz als auch in Kombination mit anderen Attraktanzien gezeigt und quantifiziert werden.
Die Fundmeldungen in Band 33 von Botanik und Naturschutz in Hessen stammen von: Dirk Bönsel, Martin de Jong, Wolfgang Ehmke, Peter Emrich, Benjamin Feller, Brunhilde Göbel, Thomas Gregor, Arthur Händler, Sylvain Hodvina, Gerwin Kasperek, Egbert Korte, Ute Lange, Stefan Meyer, Hasko Friedrich Nesemann, Uwe Raabe, Bernd Sauerwein, Marco Schmidt, Christof Nikolaus Schröder, Antje Schwab, Rainer Stoodt und Michael Uebeler.
In the current study we compared the molecular signature of expanded mesenchymal stromal cells (MSCs) derived from selected CD271+ bone marrow mononuclear cells (CD271-MSCs) and MSCs derived from non-selected bone marrow mononuclear cells by plastic adherence (PA-MSCs). Transcriptome analysis demonstrated for the first time the upregulation of 115 and downregulation of 131 genes in CD271-MSCs. Functional enrichment analysis showed that the upregulated genes in CD271-MSCs are significantly enriched for extracellular matrix (tenascin XB, elastin, ABI family, member 3 (NESH) binding protein, carboxypeptidase Z, laminin alpha 2 and nephroblastoma overexpressed) and cell adhesion (CXCR7, GPNMB, MYBPH, SVEP1, ARHGAP6, TSPEAR, PIK3CG, ABL2 and NCAM1). CD271-MSCs expressed higher gene transcript levels that are involved in early osteogenesis/chondrogenesis/adipogenesis (ZNF145, FKBP5). In addition, increased transcript levels for early and late osteogenesis (DPT, OMD, ID4, CRYAB, SORT1), adipogenesis (CTNNB1, ZEB, LPL, FABP4, PDK4, ACDC), and chondrogenesis (CCN3/NOV, CCN4/WISP1, CCN5/WISP2 and ADAMTS-5) were detected. Interestingly, CD271-MSCs expressed increased levels of hematopoiesis associated genes (CXCL12, FLT3L, IL-3, TPO, KITL). Down-regulated genes in CD271-MSCs were associated with WNT and TGF-beta signaling, and cytokine/chemokine signaling pathways. In addition to their capacity to support hematopoiesis, these results suggest that CD271-MSCs may contain more osteo/chondro progenitors and/or feature a greater differentiation potential.
A recent randomized study of whipworm Trichuris suis ova (TSO) in ileal Crohn’s disease failed to demonstrate a clinical benefit compared to placebo after 12 weeks. Nonetheless, it has recently been shown that the spontaneous small intestinal inflammatory changes in Nod2-/- (Nucleotide-binding oligomerization domain 2) mice could be substantially ameliorated when these mice were colonized by Trichuris muris. Those and complementary epidemiologic findings in humans lead to the hypothesis that helminths may be advantageous only in patients carrying defective NOD2 variants. Thus, 207 participants of the TSO trial were retrospectively genotyped for six functional NOD2 genetic variants to evaluate whether the treatment outcome differed in patients carrying NOD2 variants. We observed no significant association of the NOD2 variants or their haplotypes with clinical outcome after TSO treatment.
Aim: Pharmacoresistance is a major burden in epilepsy treatment. We aimed to identify genetic biomarkers in response to specific antiepileptic drugs (AEDs) in genetic generalized epilepsies (GGE). Materials & methods: We conducted a genome-wide association study (GWAS) of 3.3 million autosomal SNPs in 893 European subjects with GGE – responsive or nonresponsive to lamotrigine, levetiracetam and valproic acid. Results: Our GWAS of AED response revealed suggestive evidence for association at 29 genomic loci (p <10-5) but no significant association reflecting its limited power. The suggestive associations highlight candidate genes that are implicated in epileptogenesis and neurodevelopment. Conclusion: This first GWAS of AED response in GGE provides a comprehensive reference of SNP associations for hypothesis-driven candidate gene analyses in upcoming pharmacogenetic studies.